Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferator-activated receptor gamma ligands in uterine leiomyoma.
Peroxisome proliferator-activated receptor (PPAR) gamma is an important signaling molecule in cells of mesenchymal origin, inducing differentiation and regulating cell proliferation in several cell types such as vascular smooth muscle cells. Leiomyomas arise from smooth muscle cells of the uterine myometrium with an incidence rate as high as 70% in women of reproductive age. PPAR signaling has not been characterized in these tumors, although prostaglandins, natural PPAR ligands, are known effectors of key biological functions in the normal myometrium. Leiomyomas and tumor-derived cells isolated from a rat model for this disease were characterized by Western analysis and found to express all three PPAR isoforms, suggesting that signaling pathways mediated by these receptors were intact in this tumor type. In vitro experiments with a leiomyoma-derived cell line demonstrated that the pan-PPAR ligand cis-4,7,10,13,16,19-docosahexaenoic acid and PPARgamma-specific ligands 15-deoxy-delta(12,14)-prostaglandin J(2), troglitazone, and ciglitazone inhibited 17beta-estradiol-stimulated cell proliferation. This inhibitory effect was not observed with PPARalpha- or PPARbeta-specific ligands. Although both PPAR and estrogen receptor (ER) signaling pathways were intact in leiomyoma cells, in addition to growth inhibition, stimulation of PPARgamma signaling also inhibited ER-mediated gene expression. Human leiomyomas were also found to express all three PPAR isoforms, and primary cultures of these cells were sensitive to the inhibitory effects of PPARgamma ligands. These results suggest that in uterine leiomyomas PPARgamma activation is growth inhibitory and that this inhibition is mediated at least in part by negative cross-talk between ER and PPAR signaling pathways.
Houston
Kevin D
KD
University of Texas M D Anderson Cancer Center, Science Park-Research Division, Smithville, Texas 78957, USA.
Copland
John A
JA
Broaddus
Russell R
RR
Gottardis
Marco M
MM
Fischer
Susan M
SM
Walker
Cheryl Lyn
CL
D000818:Animals; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D002839:Chromans / Q000494:pharmacology; D004281:Docosahexaenoic Acids / Q000378:metabolism / Q000494:pharmacology*; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D008024:Ligands; D015230:Prostaglandin D2 / Q000031:analogs & derivatives / Q000494:pharmacology; D020033:Protein Isoforms; D051381:Rats; D018160:Receptors, Cytoplasmic and Nuclear / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000502:physiology; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors* / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D013844:Thiazoles / Q000494:pharmacology; D045162:Thiazolidinediones; D014157:Transcription Factors / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000502:physiology; D000077288:Troglitazone; D014407:Tumor Cells, Cultured; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*
C097240:15-deoxy-delta(12,14)-prostaglandin J2; D002839:Chromans; D008024:Ligands; D020033:Protein Isoforms; D018160:Receptors, Cytoplasmic and Nuclear; D011960:Receptors, Estrogen; D013844:Thiazoles; D045162:Thiazolidinediones; D014157:Transcription Factors; D004281:Docosahexaenoic Acids; D004958:Estradiol; D000077288:Troglitazone; D015230:Prostaglandin D2; C039671:ciglitazone